Association of metformin administration with gut microbiome dysbiosis in healthy volunteers
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Metformin is a widely used first-line drug for treatment of type 2 diabetes. Despite its advantages, metformin has variable therapeutic effects, contraindications, and side effects. Here, for the very first time, we investigate the short-term effect of metformin on the composition of healthy human gut microbiota. METHODS: We used an exploratory longitudinal study design in which the first sample from an individual was the control for further samples. Eighteen healthy individuals were treated with metformin (2 × 850 mg) for 7 days. Stool samples were collected at three time points: prior to administration, 24 hours and 7 days after metformin administration. Taxonomic composition of the gut microbiome was analyzed by massive parallel sequencing of 16S rRNA gene (V3 region). RESULTS: There was a significant reduction of inner diversity of gut microbiota observed already 24 hours after metformin administration. We observed an association between the severity of gastrointestinal side effects and the increase in relative abundance of common gut opportunistic pathogen Escherichia-Shigella spp. One week long treatment with metformin was associated with a significant decrease in the families Peptostreptococcaceae and Clostridiaceae_1 and four genera within these families. CONCLUSIONS: Our results are in line with previous findings on the capability of metformin to influence gut microbiota. However, for the first time we provide evidence that metformin has an immediate effect on the gut microbiome in humans. It is likely that this effect results from the increase in abundance of opportunistic pathogens and further triggers the occurrence of side effects associated with the observed dysbiosis. An additional randomized controlled trial would be required in order to reach definitive conclusions, as this is an exploratory study without a placebo control arm. Our findings may be further used to create approaches that improve the tolerability of metformin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Metagenomic biomarker discovery and explanation
Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W. S., & Huttenhower, C. (2011) · Genome Biology · doi:10.1186/gb-2011-12-6-r60 · Cited by 16,192
Standards of medical care in diabetes 2010
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s011 · Cited by 3,470
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388 · cited 2×
“…between metformin and the gut microbiome, which may be further applicable to its use across a broad range of diseases, such as Alzheimer’s disease [34], polycystic ovary syndrome [21], various types of cancers [20], and prevention of diabetes in individuals with prediabetic symptoms [35].”
Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota
MetaHIT consortium, Forslund, K., Hildebrand, F., Nielsen, T., Falony, G., Le Chatelier, E., Sunagawa, S., Prifti, E., Vieira-Silva, S., Gudmundsdottir, V., et al. (2015) · Nature · doi:10.1038/nature15766 · Cited by 2,116
Wu, H., Esteve, E., Tremaroli, V., Khan, M. T., Caesar, R., Mannerås-Holm, L., Ståhlman, M., Olsson, L. M., Serino, M., Planas-Fèlix, M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4345 · Cited by 1,632
Shin, N.-R., Lee, J.-C., Lee, H.-Y., Kim, M.-S., Whon, T. W., Lee, M.-S., & Bae, J.-W. (2014) · Gut · doi:10.1136/gutjnl-2012-303839 · Cited by 1,550
Clinical pharmacokinetics of metformin
Graham, G. G., Punt, J., Arora, M., Day, R. O., Doogue, M. P., Duong, J. K., Furlong, T. J., Greenfield, J. R., Greenup, L. C., Kirkpatrick, C. M., et al. (2011) · Clinical Pharmacokinetics · doi:10.2165/11534750-000000000-00000 · Cited by 1,318
Metformin as a tool to target aging
Barzilai, N., Crandall, J. P., Kritchevsky, S. B., & Espeland, M. A. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.05.011 · Cited by 1,096
Kirpichnikov, D., McFarlane, S. I., & Sowers, J. R. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-1-200207020-00009 · Cited by 1,084 · cited 2×
“Nevertheless, the initial side effects are the main reason for metformin discontinuation in 5% of patients [37].”
Metformin and the gastrointestinal tract
McCreight, L. J., Bailey, C. J., & Pearson, E. R. (2016) · Diabetologia · doi:10.1007/s00125-015-3844-9 · Cited by 733 · cited 2×
“Furthermore, metformin reaches a 30–300 times higher concentration in mucosa of small intestine compared to plasma, and up to 30% of the drug is eliminated through the feces [7, 8].”
Goodrich, J. K., Di Rienzi, S. C., Poole, A. C., Koren, O., Walters, W. A., Caporaso, J. G., Knight, R., & Ley, R. E. (2014) · Cell · doi:10.1016/j.cell.2014.06.037 · Cited by 714
de la Cuesta-Zuluaga, J., Mueller, N. T., Corrales-Agudelo, V., Velásquez-Mejía, E. P., Carmona, J. A., Abad, J. M., & Escobar, J. S. (2017) · Diabetes Care · doi:10.2337/dc16-1324 · Cited by 704
Moghetti, P., Castello, R., Negri, C., Tosi, F., Perrone, F., Caputo, M., Zanolin, E., & Muggeo, M. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.1.6293 · Cited by 660
Zhang, X., Zhao, Y., Xu, J., Xue, Z., Zhang, M., Pang, X., Zhang, X., & Zhao, L. (2015) · Scientific Reports · doi:10.1038/srep14405 · Cited by 630
The prevention and control the type-2 diabetes by changing lifestyle and dietary pattern
Asif, M. (2014) · Journal of Education and Health Promotion · doi:10.4103/2277-9531.127541 · Cited by 441 · cited 1×
“Also, T2D therapy accompanying a specific diet with reduced amount of simple carbohydrates [51] may play a role in limiting the amount of substrate.”
Mattila, E., Uusitalo–Seppälä, R., Wuorela, M., Lehtola, L., Nurmi, H., Ristikankare, M., Moilanen, V., Salminen, K., Seppälä, M., Mattila, P. S., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.11.037 · Cited by 371 · cited 1×
“Despite the fact that it is still hard to distinguish whether dysbiosis of the gut microbiome is the cause or consequence of T2D and a specter of various other diseases, many therapeutic effects of gut microbiome modulation have been proven already [14, 53, 54].”
Buse, J. B., DeFronzo, R. A., Rosenstock, J., Kim, T., Burns, C., Skare, S., Baron, A., & Fineman, M. (2016) · Diabetes Care · doi:10.2337/dc15-0488 · Cited by 325 · cited 1×
“In addition, a delayed-release formulation of metformin improves glycemic control to the same extent as the immediate-release form despite lower systemic exposure [9].”
Gupta, A., Bisht, B., & Dey, C. S. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.033 · Cited by 302
Morton, E. R., Lynch, J., Froment, A., Lafosse, S., Heyer, E., Przeworski, M., Blekhman, R., & Ségurel, L. (2015) · PLOS Genetics · doi:10.1371/journal.pgen.1005658 · Cited by 231 · cited 1×
“The connection between reduced alpha diversity and the further increase in the representation of opportunistic pathogens has been described before in the context of antibiotic treatment, various diseases and aging [11, 42–45].”
Gut microbiota composition is associated with polypharmacy in elderly hospitalized patients
Ticinesi, A., Milani, C., Lauretani, F., Nouvenne, A., Mancabelli, L., Lugli, G. A., Turroni, F., Duranti, S., Mangifesta, M., Viappiani, A., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-10734-y · Cited by 211
Moghetti, P., Castello, R., Negri, C., Tosi, F., Perrone, F., Caputo, M., Zanolin, E., & Muggeo, M. (2000) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-200006000-00019 · Cited by 158 · cited 2×
“…between metformin and the gut microbiome, which may be further applicable to its use across a broad range of diseases, such as Alzheimer’s disease [34], polycystic ovary syndrome [21], various types of cancers [20], and prevention of diabetes in individuals with prediabetic symptoms [35].”
Cited by
Metformin: update on mechanisms of action and repurposing potential
Foretz, M., Guigas, B., & Viollet, B. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00833-4 · Cited by 699
Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus
Foretz, M., Guigas, B., & Viollet, B. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0242-2 · Cited by 686
Bryrup, T., Thomsen, C. W., Kern, T., Allin, K. H., Brandslund, I., Jørgensen, N. R., Vestergaard, H., Hansen, T., Hansen, T. H., Pedersen, O., et al. (2019) · Diabetologia · doi:10.1007/s00125-019-4848-7 · Cited by 200
Metformin attenuated sepsis-related liver injury by modulating gut microbiota
Liang, H., Song, H., Zhang, X., Song, G., Wang, Y., Ding, X., Duan, X., Li, L., Sun, T., & Kan, Q. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2045876 · Cited by 176
“A recent study [30] showed that the abundance of Escherichia/Shigella before metformin treatment is”
BackgroundIntestinal AMPK modulation of microbiota mediates crosstalk with brown fat to control thermogenesis
Zhang, E., Jin, L., Wang, Y., Tu, J., Zheng, R., Ding, L., Fang, Z., Fan, M., Al-Abdullah, I., Natarajan, R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28743-5 · Cited by 76
Metadata
- Authors
- Elbere, I., Kalnina, I., Silamikelis, I., Konrade, I., Zaharenko, L., Sekace, K., Radovica-Spalvina, I., Fridmanis, D., Gudra, D., Pirags, V., & Klovins, J.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2018-09-27
- Volume
- 13
- Issue
- 9
- Pages
- e0204317
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2893759281
- Cited by
- 134
- References
- 22
- FWCI
- 4.79
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.